Pfizer Opening $200M Biotheraputics R&D Site in Missouri

November 22, 2016

2 Min Read
Pfizer Opening $200M Biotheraputics R&D Site in Missouri
A Pfizer facility in the United States. Image courtesy of the Montgomery County Planning Commission

Biopharmaceutical company Pfizer is planning to build a research and development site in Chesterfield, MO, consolidating the company’s two existing sites in the St. Louis-area into a unified operation, multiple news organizations reported Tuesday.

A spokesperson for the company told the St. Louis Post-Dispatch that about 625 workers, including 100 contractors, will be employed at the site, which focuses on the development of biologic therapies and vaccines.

“Missouri is an important part of Pfizer’s R&D network, and we’re proud of the world-class employee base we’ve built here,” said John Ludwig, senior vice president of Bio Therapeutics Research for Pfizer in a statement, as reported by the Post-Dispatch. “Thanks to the support we’ve received from the state of Missouri, St. Louis County and Chesterfield, our new St. Louis laboratory facility will provide the right location and space as we continue to evolve out business over the coming years.”

Construction of the 32-acre site in Chesterfield is expected to begin in 2017 and reach completion in 2020, the St. Louis newspaper said. The St. Louis Business Journal reported that the facility will occupy 460,000-sq-ft and include four to five stories.

 Pfizer cut about 600 out of 1000 jobs at its St. Louis-area facilities in 2009 as part of a move to worldwide research labs, and many positions moved to Cambridge, MA, the Post-Dispatch article noted.

Click here for information about the Powder & Bulk Solids Montreal Showcase

For related articles, news, and equipment reviews, visit our Equipment Zones

Sign up for the Powder & Bulk Solids Weekly newsletter.

You May Also Like